Aiming to pool evidence for supporting daily medical practice on the clinical management of patients affected by red blood cell disorders (RBCDs) and COVID-19,we are proud to release an upgraded version of the collaborative platform, appropriate to draw conclusions from the data already registered as well as to continue learning from new registered patients. In addition, a great number of experts have already validated the platform by the ethics committees in each country, which makes it a unique registry that we all must maintain to face this complicated situation.
Complete information on the ERN-EuroBloodNet Collaborative Platform on Red Blood Cell and COVID-19 patients is available in the dedicated section, including Scientific Committee, link to research protocol and the University Hospital Vall d'Hebrón Ethics Committee approval that can be used for any new centre willing to participate.
First relevant outcomes will be reported by October based on the first analysis of data gathered until October 15th in order to be prepared for a likely dramatic increase on number of cases next winter. Please do not hesitate to share this information with your colleagues within your country or other European countries not covered yet!
Joining the collaborative platform can be easily done following two steps. Find more information on how to access the platform in the dedicated section!
